Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Niederdorfelden, Germany Clinical Trials

A listing of Niederdorfelden, Germany clinical trials actively recruiting patients volunteers.

RESULTS

Found (74) clinical trials

IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma

This is a multicentre, placebo-controlled, double-blind, 1:1 randomised Phase IIb study in female hormone receptor-positive metastatic breast cancer patients. The study comprises of two stages. Stage 1 is the open-label, safety run-in stage consisting of cohort 1 and 2 to confirm the (RPTD) of IMP321 in combination with paclitaxel. Stage ...

Phase

4.48 miles

Learn More »

Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF

The primary hypothesis in this trial is that the treatment with vericiguat 10 mg or 15 mg in patients with HFpEF improves the KCCQ PLS (Kansas City Cardiomyopathy Questionnaire Physical limitation score) compared to placebo after 24 weeks of treatment.

Phase

4.48 miles

Learn More »

2nd TKI-stop After 2 Years Nilotinib Pre-treatment in Patients With First Unsuccessful Treatment Discontinuation in CML

The proposal is to re-treat patients with a minimum of two years with nilotinib 2x300 mg/d resulting in total of at least three years TKI treatment who show recurrent disease after unsuccessful first stop after TKI treatment in or outside the EURO-SKI study. If MR4 or better is re-achieved and ...

Phase

4.48 miles

Learn More »

Phase 2 Study of Tucatinib vs Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer

A randomized, international, multi-center, double-blinded study in patients with progressive unresectable locally advanced or metastatic HER2+ breast cancer who have had prior treatment with trastuzumab, pertuzumab and T-DM1. Patients will be randomized in a 2:1 ratio to receive tucatinib or placebo in combination with capecitabine and trastuzumab. Stratification factors include ...

Phase

6.82 miles

Learn More »

Dose EScalation Induction of EvERolimus

The BOLERO-2 study demonstrated an enormous benefit for patients who received everolimus in addition to exemestane in patients who progressed during/after a non steroidal (NSAI), which led to approval of everolimus in this indication. However, experience from routine use report a high rate of intolerability of this innovative treatment approach ...

Phase

7.03 miles

Learn More »

Varenicline for Alcohol Dependence

The varenicline for alcohol dependence trial investigates the efficacy of varenicline versus placebo for maintaining abstinence in the postacute treatment of alcohol dependent subjects. The main study hypothesis is that subjects treated with varenicline have more abstinent days during the study.

Phase

7.42 miles

Learn More »

GSK2982772 Study in Subjects With Ulcerative Colitis

This study is the first experience with GSK2982772, a receptor-interacting protein-1 (RIP1) kinase inhibitor, in subjects with active ulcerative colitis (UC). The primary objective will be to investigate the safety and tolerability of repeat oral doses of GSK2982772 60 mg or placebo three times daily for 42 days (Part A) ...

Phase

7.42 miles

Learn More »

A Six Week Efficacy Safety and Tolerability Study of V565 in Crohn's Disease

This study will be a multiple-site, double-blind, placebo-controlled, parallel-group study in approximately 126 subjects with a confirmed diagnosis of CD for at least three months and have CD involving the ileum and/or colon. Following a screening period of up to 28 days, subjects will be randomly allocated into one of ...

Phase

7.42 miles

Learn More »

Short-term Preoperative Treatment With Enzalutamide Alone or in Combination With Exemestane in Primary Breast Cancer

This study is being carried out to see if the antiandrogen enzalutamide has antitumour effects in early breast cancer. Enzalutamide blocks the action of androgens on the androgen receptor (AR) and may slow down or stop breast cancers growing. Enzalutamide is approved for the treatment of prostate cancer. The trial ...

Phase

7.42 miles

Learn More »

Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer

The current trial seeks to evaluate a new treatment option for elderly / frail elderly patients with mCRC including 5-FU - better tolerated than capecitabine in the FOCUS2 study - in conjunction with aflibercept, a broad active anti-angiogenic drug within a randomized phase-II setting. Patients will be randomized using a ...

Phase

7.42 miles

Learn More »